IFRX inflarx.de: מקדם חוב לטווח ארוך להון

InflaRx N.V. maintains a business model resilient to macroeconomic fluctuations, as R&D success remains independent of GDP cycles. This debt-to-equity chart visualizes the financial leverage, where 0.00 describes the current status of the metric. InflaRx N.V. aims to capture the orphan disease therapy niche by developing unique C5a inhibitors. The current innovation cycle is focused on molecule validation within late-stage clinical trials.

This metric is calculated as the ratio of liabilities with a maturity exceeding one year to equity, reflecting the business's dependence on external financing. It determines financial stability and the degree of risk regarding the dilution of shareholder value. For InflaRx N.V. (IFRX), low leverage is critically important when organizing complex international logistics for clinical drugs. Supply chain stability requires the absence of excessive pressure from creditors. The current long-term debt-to-equity ratio allows for an assessment of this balance.